Authors : Ritesh Fule; Prajakta Awachat

Volume/Issue : Volume 11 - 2026, Issue 3 - March

Google Scholar : https://tinyurl.com/2abavmc2

Scribd : https://tinyurl.com/8bwe35bb

DOI : https://doi.org/10.38124/ijisrt/26mar275

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Nanostructured lipid carriers containing celecoxib were prepared to treat arthritis-associated Systemic Lupus Erythematosus. CLX-NLC was formulated using hot emulsion ultrasonication method. In preparation of CLX-NLC, stearic acid (solid lipid), oleic acid (liquid lipid), and tween 80 (surfactant) were used. A three-level three-factor box Behnken design was adopted to optimize the formulated nano-structured lipid carrier system. The independent factors were solid lipid amount (X1), liquid lipid amount (X2), and surfactant amount (X3). The examined responses were entrapment efficiency (Y1, %), and particle size (Y2, nm). The optimum formula showed high entrapment efficiency of 81%, a small particle size of 138 nm, and a low polydispersity index of 0.248. FTIR spectroscopy shows that the celecoxib is compatible with other excipients like stearic acid, oleic acid, and tween 80. In DSC the melting endothermic peak of celecoxib was not observed in the thermogram of CLX-NLC showed the developed CLX-NLC formulation. The X-ray diffractogram of CLX-NLC showed decrease in intensity of the peaks which leads to amorphization of drug. SEM micrographs revealed that the surface was smooth of prepared NLC formulation and was in spherical shape nature. The in-vitro dissolution study showed a longer retention time of 15 hours in CLX-NLC. In the storage stability study, optimized CLX-NLC was found to be stable for 3 months of storage in a room and accelerated stability conditions. In vivo pharmacokinetic research in Sprague- Dawley rats displayed that the Cmax, Tmax, MRT, and AUC0-36 hrs were increased two times as compared to pure drug. Current study confirms that CLX-NLC will be an effective medication therapy for SLE patients.

Keywords : Systemic Lupus Erythematosus, Celecoxib, Nano Lipid Carrier System, Sustained Release.

References :

1. Fresneda Alarcon M, McLaren Z, Wright HL. Neutrophils in the Pathogenesis of Rheumatoid Arthritis and Systemic Lupus Erythematosus: Same Foe Different M.O. Front Immunol. 2021;12(March).
2. Lu X, Wang YH, Zhang J, Pu D, Hu N, Luo J, et al. Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: A systematic review and Meta-analysis. Int Immunopharmacol. 2021;94(January).
3. Vaglio A, Grayson PC, Fenaroli P, Gianfreda D, Boccaletti V, Ghiggeri GM, et al. Drug-induced lupus: Traditional and new concepts. Autoimmun Rev [Internet]. 2018;17(9):912–8. Available from: https://doi.org/10.1016/j.autrev.2018.03.016
4. Vale ECS do, Garcia LC. Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects. An Bras Dermatol [Internet]. 2023;(xx). Available from: https://doi.org/10.1016/j.abd.2022.09.005
5. Katz U, Zandman-Goddard G. Drug-induced lupus: An update. Autoimmun Rev [Internet]. 2010;10(1):46–50. Available from: http://dx.doi.org/10.1016/j.autrev.2010.07.005
6. Lun Hon K, Leung AKC. Neonatal lupus erythematosus. Autoimmune Dis. 2012;1(1).
7. Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatol (United Kingdom). 2021;59: V69–81.
8. Kuhn A, Bonsmann G, Anders HJ, Herzer P, Tenbrock K, Schneider M. The Diagnosis and Treatment of Systemic Lupus Erythematosus. Dtsch Arztebl Int. 2015;112(25):423–32.
9. Obrișcă B, Sorohan B, Tuță L, Ismail G. Advances in lupus nephritis pathogenesis: From bench to bedside. Int J Mol Sci. 2021;22(7).
10. Bengtsson AA, Rönnblom L. Systemic lupus erythematosus: still a challenge for physicians. J Intern Med. 2017;281(1):52–64.
11. Gururaja D, Hegde V. Ayurvedic Management of Systemic Lupus Erythematosus overlap Vasculitis. J Ayurveda Integr Med [Internet]. 2019;10(4):294–8. Available from: https://doi.org/10.1016/j.jaim.2018.08.007
12. Luan J, Zheng F, Yang X, Yu A, Zhai G. Nanostructured lipid carriers for oral delivery of baicalin: In vitro and in vivo evaluation. Colloids Surfaces A Physicochem Eng Asp [Internet]. 2015; 466:154–9. Available from: http://dx.doi.org/10.1016/j.colsurfa.2014.11.015
13. Javed S, Mangla B, Almoshari Y, Sultan MH, Ahsan W. Nanostructured lipid carrier system: A compendium of their formulation development approaches, optimization strategies by quality by design, and recent applications in drug delivery. Nanotechnol Rev. 2022;11(1):1744–77.
14. Homayouni A, Sadeghi F, Nokhodchi A, Varshosaz J, Garekani HA. Preparation and characterization of celecoxib dispersions in soluplus®: Comparison of spray drying and conventional methods. Iran J Pharm Res. 2015;14(1):35–50.
15. Taha E, Nour SA, Mamdouh W, Selim AA, Swidan MM, Ibrahim AB, et al. Cod liver oil nano-structured lipid carriers (Cod-NLCs) as a promising platform for nose to brain delivery: Preparation, in vitro optimization, ex vivo cytotoxicity & in vivo biodistribution utilizing radioiodinated zopiclone. Int J Pharm X [Internet]. 2023;5(November 2022):100160. Available from: https://doi.org/10.1016/j.ijpx.2023.100160
16. Cunha S, Loureiro JA, Alves J, Peixoto AF, Forbes B, Sousa M, et al. Double Optimization of Rivastigmine-Loaded Nanostructured Lipid Carriers (NLC) for Nose-to-Brain Delivery Using the Quality by Design (QbD) Approach: Formulation Variables and Instrumental Parameters. 2020;
17. Ali AS, Alrashedi MG, Ahmed OAA, Ibrahim IM. Pulmonary Delivery of Hydroxychloroquine Nanostructured Lipid Carrier as a Potential Treatment of COVID-19. Polymers (Basel). 2022;14(13).
18. Guo CY, Yang CF, Li QL, Tan Q, Xi YW, Liu WN, et al. Development of a Quercetin-loaded nanostructured lipid carrier formulation for topical delivery. Int J Pharm. 2012;430(1–2):292–8.
19. Madane RG, Mahajan HS. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study. Drug Deliv. 2016;23(4):1326–34.
20. Khan AA, Mudassir J, Akhtar S, Murugaiyah V, Darwis Y. Freeze-dried lopinavir-loaded nanostructured lipid carriers for enhanced cellular uptake and bioavailability: Statistical optimization, in vitro and in vivo evaluations. Pharmaceutics. 2019;11(2):1–19.
21. Luan J, Zhang D, Hao L, Li C, Qi L, Guo H, et al. Design and characterization of Amoitone B-loaded nanostructured lipid carriers for controlled drug release. Drug Deliv. 2013;20(8):324–30.
22. Arslan A, Yet B, Nemutlu E, Akdağ Çaylı Y, Eroğlu H, Öner L. Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation. Pharmaceutics. 2023;15(2).
23. Rao GD. Studies to enhance dissolution properties of Celecoxib INTERNATIONAL JOURNAL OF COMPREHENSIVE PHARMACY STUDIES TO ENHANCE DISSOLUTION PROPERTIES OF CELECOXIB. 2016;(January 2011).
24. Bhatt S, Sharma JB, Kamboj R, Kumar M, Saini V, Mandge S. Design and optimization of febuxostat-loaded nano lipid carriers using full factorial design. Turkish J Pharm Sci. 2021;18(1):61–7.
25. Agrawal M, Saraf S, Pradhan M, Patel RJ, Singhvi G, Ajazuddin, et al. Design and optimization of curcumin loaded nano lipid carrier system using Box-Behnken design. Biomed Pharmacother [Internet]. 2021;141(May):111919. Available from: https://doi.org/10.1016/j.biopha.2021.111919
26. Chauhan MK, Sharma PK. Optimization and characterization of rivastigmine nanolipid carrier loaded transdermal patches for the treatment of dementia. Chem Phys Lipids [Internet]. 2019;224(May):104794. Available from: https://doi.org/10.1016/j.chemphyslip.2019.104794
27. Mishra A, Imam SS, Aqil M, Ahad A, Sultana Y, Ameeduzzafar, et al. Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation. Drug Deliv. 2016;23(4):1486–94.
28. Madane RG, Mahajan HS. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study. Drug Deliv. 2016;23(4):1326–34.
29. Sakellari GI, Zafeiri I, Batchelor H, Spyropoulos F. Formulation design, production and characterisation of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for the encapsulation of a model hydrophobic active. Food Hydrocoll Heal [Internet]. 2021;1(August):100024. Available from: https://doi.org/10.1016/j.fhfh.2021.100024
30. Homayouni A, Sadeghi F, Nokhodchi A, Varshosaz J, Garekani HA. Preparation and characterization of celecoxib dispersions in soluplus®: Comparison of spray drying and conventional methods. Iran J Pharm Res. 2015;14(1):35–50.
31. Khan AA, Mudassir J, Akhtar S, Murugaiyah V, Darwis Y. Freeze-dried lopinavir-loaded nanostructured lipid carriers for enhanced cellular uptake and bioavailability: Statistical optimization, in vitro and in vivo evaluations. Pharmaceutics. 2019;11(2):1–19.
32. Uprit S, Kumar Sahu R, Roy A, Pare A. Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm J [Internet]. 2013;21(4):379–85. Available from: http://dx.doi.org/10.1016/j.jsps.2012.11.005
33. Arslan A, Yet B, Nemutlu E, Akdağ Çaylı Y, Eroğlu H, Öner L. Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation. Pharmaceutics. 2023;15(2).
34. G. Nava-Arzaluz M, Pinon-Segundo E, Ganem-Rondero A, Lechuga-Ballesteros D. Single Emulsion-Solvent Evaporation Technique and Modifications for the Preparation of Pharmaceutical Polymeric Nanoparticles. Recent Pat Drug Deliv Formul. 2012;6(3):209–23.
35. Arredondo-Ochoa T, Silva-Martínez GA. Microemulsion Based Nanostructures for Drug Delivery. Front Nanotechnol. 2022;3(January):1–21.
36. Schubert MA, Müller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles - Evaluation of the method and process parameters. Eur J Pharm Biopharm. 2003;55(1):125–31.
37. Ren G, Sun Z, Wang Z, Zheng X, Xu Z, Sun D. Nanoemulsion formation by the phase inversion temperature method using polyoxypropylene surfactants. J Colloid Interface Sci [Internet]. 2019; 540:177–84. Available from: https://doi.org/10.1016/j.jcis.2019.01.018